Dr. Datta is an Associate Professor of Surgery (tenure track) and a hepatobiliary, pancreatic, and gastrointestinal surgical oncologist at the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center with a focus on open and minimally invasive surgical techniques for pancreatic and metastatic liver tumors. He co-leads the Hepatic Artery Infusion Chemotherapy program at Sylvester for metastatic colorectal cancer to the liver as well as intrahepatic cholangiocarcinoma. As the Associate Director of Translational Research at the Sylvester Pancreatic Cancer Research Institute, he is also a surgeon-scientist studying myeloid immunobiology in the pancreatic cancer microenvironment. His laboratory focuses on deciphering and targeting the dominant tolerogenic myeloid cell-derived signaling mechanisms that govern T-cell dysfunction and stromal inflammation; and developing novel nanoengineering and tissue engineering strategies to abolish tolerogenic signaling in myeloid-derived suppressor cells to invigorate antitumor immune responses in pancreatic cancer. His clinical and translational research interests are in optimizing the physiologic and biologic selection of patients for neoadjuvant therapies in GI cancer, and leveraging the neoadjuvant platform to discover novel predictive biomarkers of therapeutic response.

His work has been funded by an NIH KL2 award, American College of Surgeons’ Franklin H. Martin Fellowship, Association for Academic Surgery Joel J. Roslyn Award, Society for Surgical Oncology Young Investigator Award, Elsa U. Pardee Foundation, Pancreatic Cancer Action Network Career Development Award, Department of Defense Idea Development Award, and National Cancer Institute/NIH-funded R37 MERIT award. His laboratory has recently published manuscripts in Cancer Discovery, Gastroenterology, eLife, and Oncogene, among others.